Micreos Pharmaceuticals AG, a preclinical-stage biopharmaceutical company, has entered into a strategic partnership with Northway Biotech, a Contract Development and Manufacturing Organization (CDMO), to develop scalable cGMP production processes for Micreos’ biologic therapeutic MEndoB, a first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. As part of the partnership, Northway B...